Special Issues
Table of Content

 Biomarker Discovery for Personalized Medicine in Oncology

Submission Deadline: 01 May 2026 View: 723 Submit to Special Issue

Guest Editors

Dr. Ziheng Wang

Email: zihengwang@um.edu.mo

Affiliation: MOE Frontier Science Centre for Precision Oncology, University of Macau, Macau SAR, 999078, China

Homepage:

Research Interests: Bioinformatics, Machine learning, Sequencing


Prof. Lin Zhang

Email: Lin.Zhang2@monash.edu

Affiliation: The School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3000, Australia

Homepage:

Research Interests: Health Behavior Change, Machine Learning, Natural Product Analysis, Digital Dietary Interventions, Cancer Screening


Prof. Peng Luo

Email: luopeng@smu.edu.cn

Affiliation: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Homepage:

Research Interests: Immunotherapy, Tumor Microenvironment, Machine Learning


Summary

Biomarker discovery in oncology plays a crucial role in advancing personalized medicine, offering tailored therapeutic strategies that are more effective for individual patients. With the growing understanding of cancer biology and genetics, researchers are identifying specific molecular signatures associated with tumor characteristics, patient responses, and disease progression. This ongoing research aims to uncover biomarkers that can predict treatment outcomes, enhance patient stratification, and improve overall cancer management.

Emerging technologies, including high-throughput sequencing, mass spectrometry, and advanced imaging techniques, are being leveraged to discover novel biomarkers in various cancer types. Biomarkers such as circulating tumor DNA (ctDNA), protein markers, and specific genetic alterations have shown promise in guiding targeted therapies and immunotherapies. These advancements enable oncologists to select the most appropriate treatment plans based on the unique molecular profiles of tumors.

Moreover, biomarker-driven clinical trials are increasingly focusing on patient subgroups, thereby optimizing therapeutic efficacy and minimizing adverse effects. The integration of biomarkers into clinical practice not only enhances treatment decision-making but also contributes to the development of new therapeutic agents. Ultimately, the pursuit of novel biomarkers in oncology is vital for realizing the full potential of personalized medicine, leading to improved patient outcomes and survival rates.


Keywords

Biomarker Discovery, Oncology, Personalized Medicine, Tailored Therapeutic Strategies

Published Papers


  • Open Access

    ARTICLE

    Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAFV600E Mutant A375 Melanoma Cells

    Yuanxin Miao, Fengyun Hao, Sae Hwi Ki
    Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.071034
    (This article belongs to the Special Issue:  Biomarker Discovery for Personalized Medicine in Oncology)
    Abstract Objectives: The eukaryotic initiation factor 4F (eIF4F) translation initiation complex inhibitors (eIF4Fi) were recently found to hyperactivate extracellular signal-regulated kinases 1/2 (ERK1/2) signals, which contribute to acquired resistance to BRAF (B-Raf proto-oncogene, serine/threonine kinase) inhibitors in melanoma. This present study aims to elucidate how to overcome the resistance of the eIF4Fi in BRAFV600E mutant melanoma cells and explore the underlying mechanisms. Methods: Melanoma A375 (vemurafenib [VEM]-sensitive) and A375R (VEM-resistant) cells were exposed to eIF4Fi RocA at varying doses and durations in vitro. We investigated the impact of RocA on the activity of ERK1/2, AKT serine/threonine kinase 1… More >

Share Link